Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yazeed Samara"'
Autor:
Mazyar Shadman, Allison M. Winter, Yazeed Samara, Paolo Caimi, Ryan C. Lynch, Stephen D. Smith, Brian T. Hill, Caron A. Jacobson, Matthew Mei, Alex F. Herrera, Filippo Milano, Ajay K. Gopal, Chaitra S. Ujjani, Paolo Lopedote, Austin I. Kim
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:170-175
Polatuzumab vedotin is approved therapy in the United States for relapsed/refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab (Pola+BR). However, the safety and efficacy of Pola+BR outside of a clinical trial setti
Autor:
Sarah Tomassetti, Yazeed Samara, Katie LaBarbera, Xin Qing, Richa Rathore, Alexey Aleshin, Laron McPhaul
Publikováno v:
Journal of Clinical Oncology. 40:e19552-e19552
e19552 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. With upfront treatment, 40% of patients relapse. Currently, treatment response and surveillance are monitored using positron emission tomography/computerize
Autor:
Yazeed Samara, Matthew Mei
Publikováno v:
Cancers. 14:1738
Standard treatment for relapsed and/or refractory (r/r) Hodgkin lymphoma (HL) consists of salvage therapy, historically consisting of multiagent cytotoxic chemotherapy, followed by autologous stem cell transplantation (autoHCT) in responding patients
Autor:
Yazeed Samara, Farhad M Limonadi, Omid Hamid, Constantin A Dasanu, Ion Codreanu, Juliana Alvarez-Argote
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(3)
Effective therapies for relapsed/refractory meningioma after surgery and radiation therapy represent an unmet need. Most meningiomas are highly vascularized tumors and, therefore, potentially amenable to antiangiogenic therapy. Herein, we review comp
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(4)
An important agent in melanoma therapy, ipilimumab is associated with autoimmune toxicity. Two cases of autoimmune pericarditis and large pericardial effusion have been documented with its use. Reports of myocardial toxicity have surfaced with this a